Abstract / Summary
Heart failure (HF) remains a major global health challenge, with high rates of hospitalization and mortality despite advances in therapy. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed as antidiabetic agents, have demonstrated significant cardiovascular and renal benefits across a wide range of patients. This study aims to evaluate the impact of SGLT2 inhibitors on all-cause mortality, heart failure hospitalization, and secondary outcomes, including NT-proBNP levels, left ventricular (LV) systolic function, and diuretic efficiency in patients with heart failure, irrespective of ejection fraction or diabetes status. A systematic review and a meta-analysis were conducted according to PRISMA 2020 guidelines. Electronic databases (PubMed, Embase, Cochrane CENTRAL, Scopus, and Web of Science) were searched for randomized controlled trials (RCTs) published between January 2017 and November 2025. A total of 15 eligible RCTs encompassing 28,484 participants were included. Data were extracted on clinical and functional outcomes, and pooled estimates were calculated using a DerSimonian-Laird random-effects model. Heterogeneity was assessed using the I² statistic, and publication bias was evaluated using Egger's and Begg's tests. SGLT2 inhibitor therapy was associated with a 14% reduction in all-cause mortality (HR = 0.86, 95% CI: 0.79-0.92; p < 0.001) and a 26% reduction in heart failure hospitalization (HR = 0.74, 95% CI: 0.68-0.81; p < 0.001). Heterogeneity was low for mortality (I² = 18%) and moderate for hospitalization (I² = 39%). SGLT2 inhibitors also significantly decreased the NT-proBNP levels (mean difference -168.4 pg/mL, 95% CI: -245.6 to -91.2; p < 0.001) and improved the LV systolic function (LVEF + 3.8%, 95% CI: +2.4 to +5.2; p < 0.001). Diuretic efficiency improved by an average of 480 mL/day (95% CI: +290 to +640; p = 0.002). The benefits were consistent across subgroups, including patients with HFrEF and HFpEF, with or without diabetes, and across individual SGLT2 inhibitors (empagliflozin, dapagliflozin, and sotagliflozin). No significant publication bias was detected. SGLT2 inhibitors significantly reduce the mortality and heart failure hospitalizations while improving the biomarker and cardiac function parameters, independent of diabetes status or heart failure phenotype. The consistency and magnitude of benefit confirm a class effect and support SGLT2 inhibitors as foundational therapy for heart failure across all ejection fraction categories.
Primary Source
Frontiers in endocrinology
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.